

Joseph Zohar

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9831198/joseph-zohar-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174
papers

3,990
citations

30
h-index

61
g-index

192
ext. papers

5,098
ext. citations

4
avg, IF

5.26
L-index

#	Paper	IF	Citations
174	Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. <i>Focus (American Psychiatric Publishing)</i> , 2022 , 20, 152-159	1.1	
173	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries.. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022 , 1	5.1	2
172	Neuroscience-based nomenclature of psychotropics: Progress report.. <i>European Neuropsychopharmacology</i> , 2022 , 57, 36-38	1.2	4
171	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.. <i>European Neuropsychopharmacology</i> , 2022 , 56, 100-111	1.2	2
170	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022 , 296, 485-492	6.6	
169	A prospective clinical cohort-based study of the prevalence of OCD, obsessive compulsive and related disorders, and tics in families of patients with OCD.. <i>BMC Psychiatry</i> , 2022 , 22, 190	4.2	0
168	The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network.. <i>Comprehensive Psychiatry</i> , 2022 , 116, 1523-1533	7.3	1
167	MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats.. <i>Translational Psychiatry</i> , 2022 , 12, 181	8.6	0
166	Digital psychological first aid for Ukraine.. <i>Lancet Psychiatry</i> , 2022 ,	23.3	0
165	From checking the door to checking the app: assessment and treatment implications for obsessive-compulsive disorder in the digital era. <i>CNS Spectrums</i> , 2021 , 26, 457-458	1.8	1
164	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2021 , 55, 86-95	1.2	3
163	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 114, 110480	5.5	1
162	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021 ,	5.8	1
161	Problematic use of the internet during the COVID-19 pandemic: Good practices and mental health recommendations. <i>Comprehensive Psychiatry</i> , 2021 , 112, 152279	7.3	9
160	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021 , 286, 149-157	6.6	3
159	Obsessive Compulsive Disorder During Coronavirus Disease 2019 (COVID-19): 2- and 6-Month Follow-Ups in a Clinical Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021 , 24, 703-709	5.8	7
158	Deep Transcranial Magnetic Stimulation Combined With Brief Exposure for Posttraumatic Stress Disorder: A Prospective Multisite Randomized Trial. <i>Biological Psychiatry</i> , 2021 , 90, 721-728	7.9	4

157	Is PTSD-Phenotype Associated with HPA-Axis Sensitivity? Feedback Inhibition and Other Modulating Factors of Glucocorticoid Signaling Dynamics. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
156	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021 , 38, 896-906	8.4	5
155	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 104, 110050	5.5	6
154	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021 , 279, 722-729	6.6	2
153	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 108, 110170	5.5	9
152	Melancholic features in major depression - a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021 , 110, 110285	5.5	3
151	Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology. <i>Journal of Psychiatric Research</i> , 2021 , 140, 357-363	5.2	1
150	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021 , 28, 4296-4320	4.3	1
149	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021 , 141, 167-175	5.2	3
148	Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty. <i>European Neuropsychopharmacology</i> , 2021 , 52, 72-83	1.2	
147	Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance. <i>Comprehensive Psychiatry</i> , 2020 , 100, 152180	7.3	283
146	Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. <i>International Clinical Psychopharmacology</i> , 2020 , 35, 173-193	2.2	22
145	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020 , 10, 50	8.6	16
144	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020 , 720, 134754	3.3	4
143	Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020 , 99, 109835	5.5	7
142	Add-on benzodiazepine treatment in patients with major depressive disorder - results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020 , 41, 70-80	1.2	9
141	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020 , 23, 571-577	5.8	2
140	Effects of agomelatine on behaviour, circadian expression of period 1 and period 2 clock genes and neuroplastic markers in the predator scent stress rat model of PTSD. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 255-273	3.8	2

139	Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , 2020 , 25, 419-425	1.8	5
138	Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2019 , 176, 931-938	11.9	116
137	Major Depression and Comorbid Diabetes - Findings from the European Group for the Study of Resistant Depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019 , 94, 109638	5.5	11
136	Comorbid hypertension in patients with major depressive disorder - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2019 , 29, 777-785	1.2	12
135	Temperament and character influence on depression treatment outcome. <i>Journal of Affective Disorders</i> , 2019 , 252, 464-474	6.6	14
134	Discrepancies Between Nomenclature and Indications of Psychotropics. <i>Pharmacopsychiatry</i> , 2019 , 52, 175-179	2	2
133	Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019 , 20, 427-448	3.8	51
132	Psychotic Features in Patients With Major Depressive Disorder: A Report From the European Group for the Study of Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	18
131	Early intervention for obsessive compulsive disorder: An expert consensus statement. <i>European Neuropsychopharmacology</i> , 2019 , 29, 549-565	1.2	54
130	Attrition in treatment-resistant depression: predictors and clinical impact. <i>International Clinical Psychopharmacology</i> , 2019 , 34, 161-169	2.2	
129	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019 , 214, 36-41	5.4	24
128	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 93-104	5.8	14
127	Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD). <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 539-549	5.8	32
126	Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD). <i>European Neuropsychopharmacology</i> , 2018 , 28, 752-760	1.2	25
125	Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study. <i>Journal of Affective Disorders</i> , 2018 , 227, 254-259	6.6	5
124	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 81, 203-210	5.5	20
123	Clinical and electrophysiological outcomes of deep TMS over the medial prefrontal and anterior cingulate cortices in OCD patients. <i>Brain Stimulation</i> , 2018 , 11, 158-165	5.1	99
122	Secondary Prevention of Chronic PTSD by Early and Short-Term Administration of Escitalopram: A Prospective Randomized, Placebo-Controlled, Double-Blind Trial. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	12

121	Refining Prediction in Treatment-Resistant Depression: Results of Machine Learning Analyses in the TRD III Sample. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	58
120	Adjunctive treatment with brexpiprazole and escitalopram reduces behavioral stress responses and increase hypothalamic NPY immunoreactivity in a rat model of PTSD-like symptoms. <i>European Neuropsychopharmacology</i> , 2018 , 28, 63-74	1.2	18
119	Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2018 , 227, 777-786	6.6	20
118	Neuropeptide S in the basolateral amygdala mediates an adaptive behavioral stress response in a rat model of posttraumatic stress disorder by increasing the expression of BDNF and the neuropeptide YY1 receptor. <i>European Neuropsychopharmacology</i> , 2018 , 28, 159-170	1.2	13
117	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants. <i>Human Psychopharmacology</i> , 2018 , 33, e2682	2.3	6
116	Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study. <i>European Neuropsychopharmacology</i> , 2018 , 28, 1305-1313	1.2	13
115	Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018 , 86, 36-44	5.5	30
114	Evidence-based national suicide prevention taskforce in Europe: A consensus position paper. <i>European Neuropsychopharmacology</i> , 2017 , 27, 418-421	1.2	27
113	Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study. <i>Journal of Psychiatric Research</i> , 2017 , 91, 1-13	5.2	46
112	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017 , 267, 723-735	5.1	14
111	A new nomenclature for classifying psychotropic drugs. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1614-1616	3.8	15
110	The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study. <i>European Neuropsychopharmacology</i> , 2017 , 27, 625-632	1.2	14
109	Inverse agonists - What do they mean for psychiatry?. <i>European Neuropsychopharmacology</i> , 2017 , 27, 87-90	1.2	10
108	Acute Optic Neuropathy and Development of Posttraumatic Stress Disorder. <i>Seminars in Ophthalmology</i> , 2017 , 32, 400-406	2.4	
107	Preventing sleep on the first resting phase following a traumatic event attenuates anxiety-related responses. <i>Behavioural Brain Research</i> , 2017 , 320, 450-456	3.4	24
106	A New Prediction Model for Evaluating Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 215-222	4.6	49
105	Behavioural addiction-A rising tide?. <i>European Neuropsychopharmacology</i> , 2016 , 26, 841-55	1.2	60
104	Standards of care for obsessive-compulsive disorder centres. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016 , 20, 204-8	2.4	11

103	Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers - A pharmacoepidemiological cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2016 , 26, 1960-1971	1.2	33
102	Suicide prevention strategies revisited: 10-year systematic review. <i>Lancet Psychiatry</i> , 2016 , 3, 646-59	23.3	773
101	Bipolar II disorder as a risk factor for postpartum depression. <i>Journal of Affective Disorders</i> , 2016 , 204, 54-8	6.6	22
100	Predator-scent stress, ethanol consumption and the opioid system in an animal model of PTSD. <i>Behavioural Brain Research</i> , 2016 , 306, 91-105	3.4	27
99	Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. <i>Journal of Affective Disorders</i> , 2016 , 189, 224-32	6.6	54
98	Distinctive cardiac autonomic dysfunction following stress exposure in both sexes in an animal model of PTSD. <i>Behavioural Brain Research</i> , 2016 , 308, 128-42	3.4	12
97	Neuroscience-based Nomenclature (NbN): A call for action. <i>World Journal of Biological Psychiatry</i> , 2016 , 17, 318-20	3.8	10
96	What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 472-82	3.8	14
95	Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial. <i>BMC Psychiatry</i> , 2015 , 15, 24	4.2	28
94	Beyond the HPA-axis: The role of the gonadal steroid hormone receptors in modulating stress-related responses in an animal model of PTSD. <i>European Neuropsychopharmacology</i> , 2015 , 25, 944-57	1.2	22
93	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015 , 25, 2318-25	1.2	89
92	Early post-stressor intervention with minocycline, a second-generation tetracycline, attenuates post-traumatic stress response in an animal model of PTSD. <i>European Neuropsychopharmacology</i> , 2015 , 25, 124-32	1.2	40
91	Diurnal fluctuations in HPA and neuropeptide Y-ergic systems underlie differences in vulnerability to traumatic stress responses at different zeitgeber times. <i>Neuropsychopharmacology</i> , 2015 , 40, 774-90	8.7	38
90	Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression. <i>Journal of Affective Disorders</i> , 2015 , 184, 51-9	6.6	30
89	The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression. <i>European Neuropsychopharmacology</i> , 2015 , 25, 441-53	1.2	58
88	Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015 , 13, 48-52	3.4	11
87	Blunting of the HPA-axis underlies the lack of preventive efficacy of early post-stressor single-dose Delta-9-tetrahydrocannabinol (THC). <i>Pharmacology Biochemistry and Behavior</i> , 2014 , 122, 307-18	3.9	12
86	Treatment with Ziprasidone for schizophrenia patients with OCD. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1454-62	1.2	12

85	Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. <i>Journal of Psychopharmacology</i> , 2014 , 28, 596-602	4.6	40
84	Mortality rates between treated post-traumatic stress disorder Israeli male veterans compared to non-diagnosed veterans. <i>European Neuropsychopharmacology</i> , 2014 , 24, 117-24	1.2	3
83	The different faces of Creutzfeldt-Jacob disease CJD in psychiatry. <i>General Hospital Psychiatry</i> , 2014 , 36, 245-8	5.6	13
82	Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>Comprehensive Psychiatry</i> , 2014 , 55, 1513-9	7.3	77
81	Distinctive hippocampal and amygdalar cytoarchitectural changes underlie specific patterns of behavioral disruption following stress exposure in an animal model of PTSD. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1925-44	1.2	42
80	Immediate ketamine treatment does not prevent posttraumatic stress responses in an animal model for PTSD. <i>European Neuropsychopharmacology</i> , 2014 , 24, 469-79	1.2	30
79	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1005-14	1.2	60
78	High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies. <i>European Neuropsychopharmacology</i> , 2011 , 21, 796-809	1.2	203
77	Stress and Animal Models of Posttraumatic Stress Disorder 2011 , 388-409		
76	New insights into secondary prevention in post-traumatic stress disorder. <i>Dialogues in Clinical Neuroscience</i> , 2011 , 13, 301-9	5.7	68
75	Risk factors for the development of posttraumatic stress disorder following combat trauma: a semipropective study. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 1629-35	4.6	21
74	Can posttraumatic stress disorder be prevented?. <i>CNS Spectrums</i> , 2009 , 14, 44-51	1.8	26
73	Early post-stressor intervention with high-dose corticosterone attenuates posttraumatic stress response in an animal model of posttraumatic stress disorder. <i>Biological Psychiatry</i> , 2008 , 64, 708-717	7.9	139
72	Brief post-stressor treatment with pregabalin in an animal model for PTSD: short-term anxiolytic effects without long-term anxiogenic effect. <i>European Neuropsychopharmacology</i> , 2008 , 18, 653-66	1.2	31
71	Escitalopram in the treatment of obsessive-compulsive disorder. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 339-49	4.3	9
70	Post-traumatic stress disorder: facts and fiction. <i>Current Opinion in Psychiatry</i> , 2008 , 21, 74-7	4.9	21
69	OCD: Towards DSM-V. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007 , 11 Suppl 2, 1-4	2.4	3
68	The Epidemiology of Mood Disorders 2005 , 1-34		1

- 67 The Treatment of Depression **2005**, 291-350
- 66 Psychological Treatments of Depression **2005**, 351-371
- 65 Treatment-Resistant Mood Disorders: From Diagnosis to Treatment **2005**, 373-401
- 64 Brain Stimulation in Depression **2005**, 403-425 1
- 63 Potential Targets for the Treatment of Depressive Disorders **2005**, 427-448
- 62 Sleep Research and Affective Disorders **2005**, 449-465
- 61 Implementing Clinical Trials **2005**, 467-489
- 60 Mood and Anxiety Disorders **Is Diagnostic Pleonasm?** **2005**, 491-502 1
- 59 At the Interface of Depression and Anxiety: Comorbidity and Concepts **2005**, 503-526 1
- 58 Genetics of Mood Disorders **2005**, 35-75 1
- 57 Unipolar Depression **2005**, 77-101 0
- 56 Subthreshold Mood Disorders **2005**, 117-143
- 55 Suicidal Behaviour **2005**, 145-188 1
- 54 Stress and Depression: The Inflammatory Hypothesis **2005**, 211-228
- 53 Brain Imaging in Affective Disorders **2005**, 229-289
- 52 Neurobiology of Depression **2005**, 189-210
- 51 Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. *Journal of Clinical Psychiatry*, **2004**, 65 Suppl 14, 18-21 4.6 8
- 50 Diagnosis of Obsessive-Compulsive Disorder: A Review **2003**, 1-41 2

49	Pharmacological Treatment of Obsessive-Compulsive Disorder: A Review 2003 , 43-92		
48	Psychotherapies for Obsessive-Compulsive Disorder: A Review 2003 , 93-146		2
47	Child and Adolescent Obsessive-Compulsive Disorder: A Review 2003 , 147-201		2
46	Obsessive-Compulsive Spectrum Disorders: A Review 2003 , 203-252		4
45	Costs of Obsessive-Compulsive Disorder: A Review 2003 , 253-299		5
44	Posttraumatic stress disorder: a hidden epidemic. <i>CNS Spectrums</i> , 2003 , 8, 634	1.8	1
43	Acknowledgements for the First Edition 2003 , 301-301		
42	Researching schizophrenia: the difficulty of subtyping. <i>CNS Spectrums</i> , 2002 , 7, 20	1.8	
41	Extending neuropsychological testing. <i>CNS Spectrums</i> , 2002 , 7, 337	1.8	
40	Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 190-5	1.7	137
39	Developing cross-national CME for mental disorders in Europe. <i>European Psychiatry</i> , 2001 , 16, 255-6	6	1
38	Screening for new antidepressants with fast onset and long-lasting action. <i>Drug Development Research</i> , 2000 , 50, 392-399	5.1	14
37	Update on the epidemiology, diagnosis, and treatment of posttraumatic stress disorder. <i>Dialogues in Clinical Neuroscience</i> , 2000 , 2, 37-43	5.7	4
36	Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. <i>British Journal of Psychiatry</i> , 1996 , 169, 468-74	5.4	197
35	Is Caffeine Involved in the Pathogenesis of Combat-Stress Reaction?. <i>Military Medicine</i> , 1996 , 161, 230-232		4
34	Current concepts in the pharmacological treatment of obsessive-compulsive disorder. <i>Drugs</i> , 1992 , 43, 210-8	12.1	58
33	Factors influencing sexual activity after prostatectomy: a prospective study. <i>Journal of Urology</i> , 1976 , 116, 332-4	2.5	59
32	Learning Perspectives on Anxiety Disorders 245-264		3

31	Specific Phobias105-135	
30	Social Phobia137-155	
29	Epidemiology of Anxiety Disorders1-23	1
28	Panic Disorder: Clinical Course, Morbidity and Comorbidity51-79	3
27	Generalised Anxiety Disorder187-204	2
26	Post-Traumatic Syndromes: Comparative Biology and Psychology205-221	
25	Obsessive-Compulsive Disorder: Diagnostic Considerations and an Epidemiological Update157-168	
24	Genetics of Anxiety Disorders: Part I25-40	
23	Panic Disorder: Pathogenesis and Treatment81-103	1
22	The Experience Sampling Method in Stress and Anxiety Research289-306	3
21	Genetics of Anxiety Disorders: Part II41-50	
20	A Case Study of the 35% CO ₂ Challenge339-357	5
19	Obsessive-Compulsive Disorder: Biology and Treatment, a Generation of Progress169-186	
18	Clinical Testing of Anxiolytic Drugs325-337	1
17	The Pharmacology of Human Anxiety309-324	2
16	Current Trends in Cognitive Behaviour Therapy for Anxiety Disorders265-286	
15	Brain Imaging244-276	
14	Neurocognitive Angle: The Search for Endophenotypes300-326	

13	Conclusion and Future Directions327-330	
12	Pharmacotherapy of Obsessive-Compulsive Disorder31-57	
11	Paediatric OCD: Developmental Aspects and Treatment Considerations160-189	
10	Serotonin and Beyond: A Neurotransmitter Perspective of OCD220-243	
9	Cognitive Behavioural Therapy in Obsessive-Compulsive Disorder: State of the Art58-74	0
8	The Genetics of Obsessive-Compulsive Disorder: Current Status277-299	1
7	Electroconvulsive Therapy, Transcranial Magnetic Stimulation and Deep Brain Stimulation in OCD75-98	1
6	Approaches to Treatment Resistance99-131	1
5	Subtypes and Spectrum Issues133-159	2
4	Methodological Issues for Clinical Treatment Trials in Obsessive-Compulsive Disorder191-219	1
3	The Psychobiology of Post-Traumatic Stress Disorder223-244	
2	The Tryptophan Depletion Technique in Psychiatric Research359-369	
1	Post-Traumatic Stress Disorder in Animal Models261-282	